Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-211 in Malignant Solid Tumors
NCT05727839Phase 1Completed
- Sponsor
- Immorna
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of JCXH-211 in malignant solid tumor, sponsored by Immorna. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events. Started Feb 2023; status: completed.
02
Drugs
JCXH-211
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05727839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727839.